Table 1.

Overview of current literature using PDDU – Intracavernosal agent, dose and rigidity assessment

		Number of studies (Percentage of total)
Intracavernosal Agent	Prostaglandin	43 (50%)
	Papaverine	14 (16.3%)
	Trimix	10 (11.6%)
	Bimix	6 (7%)
	Multiple	3 (3.5%)
	NR	10 (11.6%)
Re-dosing protocol	Yes	22 (25.6%)
	No	64 (74.4%)
Max number of doses	2	9 (10.5%)
	3	5 (5.8%)
	NR	72 (83.7%)
Rigidity Assessment	None	48 (55.8% )
	EHS	12 (13.9%)
	0-10	4 (4.6%)
	0-5	3 (3.5%)
	Method NR	19 (22.1%)
BQE mentioned	Yes	9 (10.5% )
	No	77 (89.5%)

NR = Not reported, EHS = Erection Hardness Score, BQE = Best quality erection